Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer.

Therapeutics and clinical risk management·2021
Same author

Evaluating the safety and potential activity of URO-902 (hMaxi-K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non-neurogenic) overactive bladder syndrome and detrusor overactivity from two double-blind, imbalanced, placebo-controlled randomized phase 1 trials.

Neurourology and urodynamics·2020
Same author

The Effects of a Genital Vibratory Stimulation Device on Sexual Function and Genital Sensation.

Female pelvic medicine & reconstructive surgery·2016
Same author

Calcified central venous catheter fibrin sheath: case report and review of the literature.

Clinical imaging·2015
Same author

Diabetes attenuates urothelial modulation of detrusor contractility and spontaneous activity.

International journal of urology : official journal of the Japanese Urological Association·2014
Same author

Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2014

Related Experiment Video

Updated: May 26, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Novel therapeutic targets for erectile dysfunction.

Steve K Williams1, Arnold Melman

  • 1Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA.

Maturitas
|December 14, 2011
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED) research is advancing, focusing on the neurovascular mechanisms of penile erection. New oral pharmacotherapies, including melanocortins and Rho-kinase inhibitors, show promise for treating male ED.

Related Experiment Videos

Last Updated: May 26, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Urology
  • Pharmacology
  • Neuroscience

Background:

  • Erectile dysfunction (ED) is a complex neurovascular condition influenced by hormonal, biochemical, and structural factors.
  • The success of phosphodiesterase inhibitors has spurred further research into erectile physiology.
  • Understanding central and peripheral pathways controlling penile erection has improved significantly.

Purpose of the Study:

  • To review recent pharmacological advances in the oral treatment of male erectile dysfunction.
  • To highlight novel therapeutic strategies emerging from ongoing research.

Main Methods:

  • Literature review of current research on erectile dysfunction pharmacotherapy.
  • Analysis of preclinical and early clinical trial data for novel agents.

Main Results:

  • Significant progress in understanding the neurovascular mechanisms of penile erection.
  • Emerging oral pharmacotherapies like melanocortins and Rho-kinase inhibitors show efficacy.
  • Gene therapy and tissue engineering are also demonstrating potential in ED management.

Conclusions:

  • Novel oral pharmacotherapies represent a promising frontier in managing male erectile dysfunction.
  • Continued research into erectile physiology is crucial for developing more effective treatments.